Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay

Table 1 Number of aPL antibody positive sera investigating 85 APS patients, 65 DC patients, and 79 NHS in ELISA and in the MLDA

	ELISA					MLDA									ELISA or MDLA
	anti-CL		anti-β2 GPI		anti-CL or anti-β2 GPI	anti-PS		anti-PI		anti-CL		anti-β2 GPI		anti-PS, anti-PI, anti-CL or anti-β2 GPI
	IgG	IgM	IgG	IgM		IgG	IgM	IgG	IgM	IgG	IgM	IgG	IgM
APS n = 85	45	32	27	33	50	28	17	7	3	39	33	31	27	57	63
DC n = 65	1	1	0	0	1	1	0	0	0	2	3	0	3	7	8
NHS n = 79	1	0*	0	4	5	1	1	0	0	2	6*	0	5	8	12

* P < 0.05 for the comparison of ELISA and MLDA
APS, antiphospholipid syndrome; anti-β2 GPI, anti-beta2-glycoprotein I; anti-CL, anti-cardiolipin; anti-PI, anti-phosphatidylinositol; anti-PS, anti-phosphatidylserine; DC, disease controls; ELISA, enzyme-linked immunosorbent immunoassay; MLDA, multi-line dot assay; NHS, normal healthy subjects.

ISSN: 1478-6362